Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOHT5V)

• Drug Name: DKN-01 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Biliary tract cancer	2C17	Phase 2	[1]
Endometrial cancer	2C76	Phase 2	[2]
Esophageal cancer	2B70	Phase 2	[1]
Ovarian cancer	2C73	Phase 2	[2]
Cholangiocarcinoma	2C12.10	Phase 1/2	[3]
Multiple myeloma	2A83	Phase 1/2	[4]
Oesophagogastric junction cancer	2B71.Z	Phase 1/2	[2]
Prostate cancer	2C82.0	Phase 1/2	[5]

• Cross-matching ID: TTD Drug ID: DMOHT5V

Molecule-Related Drug Atlas

Drug(s) Targeting Dickkopf-related protein 1 (DKK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BHQ880	DMSROM4	Multiple myeloma	2A83	Phase 2	[7]
PF-04840082	DMDSCQG	Osteoporosis	FB83.0	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dickkopf-related protein 1 (DKK1)	TTE3RAC	DKK1_HUMAN	Inhibitor	[6]

References

• [1] ClinicalTrials.gov (NCT03818997) Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03837353) A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. U.S. National Institutes of Health.
• [6] The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.
• [7] Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9.
• [8] The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13.